Modern Organic Chemistry Research

Download PDF (545.4 KB) PP. 10 - 23 Pub. Date: November 17, 2016

DOI: 10.22606/mocr.2016.11002

• Dorota Bartusik^*
  Southern Polytechnic State University, Department of Biology and Chemistry, 1100 South Marietta Parkway, Marietta, Georgia 30060, USA
• David Aebisher
  Shorter University, Natural Sciences Department, 315 Shorter Ave, Rome, Georgia 30165, USA
• Piotr Tutka
  University of Rzeszów, Department of Pharmacology, Al. Rejtana 16C, 35-959 Rzeszów, Poland

Cytisine, nicotinic acetylcholinergic receptors, alkaloid

Cytisine (CYT) is a naturally occurring chiral alkaloid which is known to be a ligand of nicotinic acetylcholinergic receptors (nAChRs). This compound has been a subject of quite intensive pharmacological research to explore CYT impact on the nAChRs. CYT may be a both more clinically effective and more cost-effective smoking cessation aid than varenicline (the most effective, but most expensive smoking cessation medication currently available), which belongs to the same category of agonists. Several strategies have been developed for the synthesis of CYT and its derivatives. Herein we review the strategies that have been employed for the synthetic formation of the tricyclic CYT molecule. Synthetic approaches include the formation of (±)-CYT from bipyridines, synthesis of (+)-CYT using chiral pools and the use of microorganisms to synthesize (-)-CYT. Due to the clinical importance of CYT, we hope a review of synthetic pathways may advance research into CYT.

[1] P. Tutka, W. Zaton?ski, “Cytisine for the treatment of nicotine addiction: from molecule to therapeutic efficacy”, Pharmacology Report, vol. 58, pp.777-798, 2006.

[2] J.J. Prochaska, S. Das, N.L. Benowitz, “Cytisine, the world’s oldest smoking cessation aid”, BMJ, vol. 347, pp. 5198, 2013.

[3] E. Beard, L. Shahab, D.M. Cummings, Susan Michie, Robert West, “New Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What Has Been Investigated, and What Is in the Pipeline? ” CNS Drugs. pp. 1-33, doi:10.1007/s40263-016-0362-3, 2016.

[4] P. Tutka, “Nicotinic receptors partial agonists as novel compounds for the treatment of smoking cessation”, Expert Opinion on Investigational Drugs, vol. 17, pp. 1473-1485, 2008.

[5] P. Aveyard, R. West, “Cytisine and the failure to market and regulate for human health”, Thorax, vol. 68, pp. 989, 2013.

[6] P. Hajek, H. McRobbie, K. Myers, “Efficacy of cytisine in helping smokers quit: systemic review and metaanalysis”, Thorax, vol. 68, pp.1037-1042, 2013.

[7] J.A. Stapleton,“The case for licensing cytisine now for smoking cessation is overwhelming”, BMJ, vol. 347, pp. 5736, 2013.

[8] N. Walker, C. Howe, M. Glover, H. McRobbie, J. Barnes, V. Nosa, V. Parag, B. Bassett, C. Bullen, “Cytisine versus nicotine for smoking cessation”, New England Journal of Medicine, vol. 371, pp. 2353-2362, 2014.

[9] N. Walker, C. Bullen, J. Barnes, H. McRobbie, P. Tutka, M. Raw, J.F. Etter, K. Siddiqi, R.J. Courtney, J. M. Castaldelli-Maia, P. Selby, J. Sheridan, N.A. Rigotti, “Getting cytisine licensed for use world-wide: a call to action”, Addiction. doi: 10.1111/add.13464, 2016.

[10] A. Husemann, A. Marmé,. “Cytisine”, Ed in. Ned Journal, vol. 7, pp. 1025, 1862.

[11] A. Partheil, “Zur Frage der Identit?t von Cytisin und Ulexin”, Archives of Pharmacy, vol. 232, pp. 486-488, 1894.

[12] M. Freund, A. Friedmann, “Zur Kenntnis des Cytisins”, Berichte der deutschen chemischen Gesellschaft, vol. 34, pp. 605-619, 1901.

[13] H.R. Ing, “Cytisine part I”, Journal of Chemical Society, pp. 2195-2203, 1931.

[14] H.R. Ing, “Cytisine part II”, Journal of Chemical Society, pp. 2778- 2780, 1932.

[15] M. Sp?th, “4-hydroxy-6,8-dimethylquinoline”. Montash, vol. 40, pp. 93, 1919.

[16] A. Partheil, “Ueber das Cytisin”, Berichte der deutschen chemischen Gesellschaft, vol. 23(2), pp. 3201–3203, 1890.

[17] F. Galinovsky, E. Stern, “über die katalytische Reduktion einiger Alkaloide der Sparteingruppe, die einen Lactam- oder α-Pyridonring enthalten”, Berichte der deutschen chemischen Gesellschaft, vol. 77, pp. 132-138, 1944.

[18] N.J. Leonard. In The Alkaloids; R. H. F. Manske, H.L. Holmes, Eds.; Academic Press: New York, Vol. 3, pp 119-199, 1953.

[19] E.E. Van Tamelen, J.S. Baren, “The synthesis of dl-cytisine”, Journal of American Chemical Society, vol. 77, pp. 4944-4945, 1955.

[20] D.J Anderson, S.P. Arneric, “Nicotinic receptor binding of [3H]cytisine, [3H]nicotine and [3H]methylcarbamylcholine in rat brain”, European Journal of Pharmacology, vol. 253, pp. 261-267, 1994.

[21] J.W. Coe, P.R. Brooks, M.G. Vetelino, M.C. Wirtz, E.P. Arnold, J. Huang, S.B. Sands, T.I. Davis, L.A. Lebel, C.B. Fox, A. Shrikhande, J.H. Heym, E. Schaeffer, H. Rollema, Y. Lu, R.S. Mansbach, L.K. Chambers, C.C. Rovetti, D.W. Schulz, F.D. Tingley, B.T. O’Neill, “Varenicline, an R4β2 nicotinic receptor partial agonist for smoking cessation”, Journal of Medicinal Chemistry, vol. 48, pp. 3474-3477, 2005.

[22] R. West, W. Zatoński, M. Cedzyńska, D. Lewandowska, J. Pazik, P. Aveyard, J. Stapleton, “Placebo-controlled trial of cytisine for smoking cessation”, New England Journal of Medicine, vol. 365, pp. 1193-1200, 2011.

[23] J.W. Coe, “Total synthesis of (±)-cytisine via the intramolecular heck cyclization of activated N-alkyl glutarimides”, Organic Letters vol. 2, pp. 4205-4208, 2000.

[24] B.T. O’Neill, D. Yohannes, M.W. Bundesmann, E.P. Arnold, “Total synthesis of (±)-cytisine”, Organic Letters, vol. 2, pp. 4201, 2000.

[25] D. Gray, T. Gallagher, “A flexible strategy for the synthesis of tri- and tetracyclic lupin alkaloids: synthesis of (+)-cytisine, (+/-)-anagyrine, and (+/-)-thermopsine”, Angewandte Chemie International Edition, vol. 45, pp. 2419-2423, 2006.

[26] B. Danieli, G. Lesma, D. Passarella, A. Sacchetti, A. Silvani, A. Virdis,“Total Enantioselective Synthesis of (?)-Cytisine”, Organic Letters, vol. 6, pp. 493-496, 2004.

[27] T. Honda, R. Takahashi, H. Namiki, “Syntheses of (+)-Cytisine, (-)-Kuraramine, (-)-Isokuraramine, and (-)-Jussiaeiine”, Journal of Organic Chemistry, vol. 70, pp. 499-504, 2005.

[28] E.G. Pérez, C. Méndez-Gálvez, B.K. Cassels, “Cytisine: a natural product lead for the development of drugs acting at nicotinic acetylcholine receptors”, Natural Products Reports, vol. 29, pp. 555-567, 2012.

[29] L.F. Yu, H.K. Zhang, B.J. Caldarone, J.B. Eaton, R.J. Lukas, A.P. Kozikowski, “Recent developments in novel antidepressants targeting α 4β 2-nicotinic acetylcholine receptors”, Journal of Medicinal Chemistry, vol. 57, pp. 8204-8223, 2014.

[30] P. Imming, P. Klaperski, M.T. Stubbs, G. Seitz, D. Gu?ndisch, Syntheses and evaluation of halogenated cytisine derivatives and of bioisosteric thiocytisine as potent and selective nAChR ligands”, European Journal of Medicinal Chemistry, vol. 36, pp. 375-388, 2001.

[31] M.R. Picciotto, M. Zoli, R. Rimondini, C. Léna, L.M. Marubio, E.M. Pich, K. Fuxe, J.P. Changeux, “Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine”, Nature vol. 391, pp. 173-177, 1998.

[32] N.L. Benowitz,“Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction”, Clinical Pharmacology Therapy, vol. 83, pp. 531-541, 2008.

[33] T.S. Rao, L.D. Correa, P. Adams, E.M. Santori, A.I. Sacaan, “Pharmacological characterization of dopamine, norepinephrine and serotonin release in rat prefrontal cortex by neuronal nicotinic acetylcholine receptor agonists”, Brain Research, vol. 990, pp. 203-208, 2003.

[34] C. Cohen, O.E. Bergis, F. Galli, A.W. Lochead, S. Jegham, B. Biton, J. Leonardon, P. Avenet, F. Sgard, F. Besnard, D. Graham, A. Coste, A. Oblin, O. Curet, C. Voltz, A. Gardes, D. Caille, G. Perrault, P. George, P. Soubrie, B. Scatton. “SSR591813, a novel selective and partial alpha4beta2 nicotinic receptor agonist with potential as an aid to smoking cessation”, Journal of Pharmacology and Experimental Therapeutics, vol. 306, pp. 407-420, 2003.

[35] H. Rollema, A. Shrikhande, K.M. Ward, F.D. Tingley, J.W. Coe, B.T. O'Neill, E. Tseng, E.Q. Wang, R.J. Mather, R.S. Hurst, K.E. Williams, M. de Vries, T. Cremers, S. Bertrand, D. Bertrand, “Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence”, British Journal of Pharmacology, vol. 160, pp. 334-345, 2010.

[36] I. Hanin, R. Cacabelos, A. Fisher, “Recent Progress in Alzheimer's and Parkinson's Diseases. London: Taylor and Francis, pp. 383. ISBN 1-84184-320-2, 2005.

[37] T.C. Durazzoa, N. Mattssona, M.W. Weinera, Smoking and increased Alzheimer's disease risk: “A review of potential mechanisms”, Alzheimer's & Dementia, vol. 10(3), pp. S122–S145, 2014.

[38] C. Reavill, B. Walther, I.P. Stolerman, B. Testa, “Behavioral and pharmacokinetic studies on nicotine, cytisine and lobeline”, Neuropharmacology, vol. 29, pp. 619-624, 1990.

[39] H. Rollema, J.W. Coe, L.K. Chambers, R.S. Hurst, S.M. Stahl, K.E. Williams, “Rationale, pharmacology and clinical efficacy of partial agonists of alpha4beta2 nACh receptors for smoking cessation”, Trends in Pharmacological Sciences, vol. 28, pp. 316-325, 2007.

[40] C.C. Boido, F. Sparatore, “Synthesis and preliminary pharmacological evaluation of some cytisine derivatives”, Il Farmaco vol. 54, pp. 438-451, 1999.

[41] E. Marrie?re, J. Rouden, V. Tadino, M. –C. Lasne, “Synthesis of analogues of (-)-cytisine for in vivo studies of nicotinic receptors using positron emission tomography”, Organic Letters, vol. 2, pp. 1121-1124, 2000.

[42] J. Rouden, A. Ragot, S. Gouault, D. Cahard, J.-C. Plaquevent, M.-C. Lasne, “Regio- and diastereoselective functionalization of (-)-cytisine: an unusual N–C acyl migration”, Tetrahedron: Asymmetry vol. 13, pp. 1299-1305, 2002.

[43] C.C. Boido, B. Tasso, V. Boido, F. Sparatore, “Cytisine derivatives as ligands for neuronal nicotine receptors and with various pharmacological activities”, Farmaco, vol. 58, pp. 265-277, 2003.

[44] A.A. Freer, D.J. Robins, G.N. Sheldrake, “Structures of (-)-cytisine and (-)-N-methylcytisine: tricyclic quinolizidine alkaloids”, Acta Crystallographica, vol. 43, pp. 1119-1122, 1987.

[45] F. Bohlmann, A. English, N. Ottawa, H. Sander, W. Weise. “Lupinenalkaloide, IV. Totalsynthese der Cytisins (Zur Synthese des Cytisins, III.), Berichte der deutschen chemischen Gesellschaft, vol. 89, pp. 792-799, 1956.

[46] T.R. Govindachari, S. Rajadurai, M. Subramanian, B.S. Thyagarajan, “Syntheses of protoberberine alkaloids”, Journal of Chemical Society, pp. 3839-3844, 1957.

[47] D. Stead, P. O'Brien, A. Sanderson, “Concise synthesis of (+/-)-cytisine via lithiation of N-Boc-bispidine”, Journal of Organic Letters, vol. 7, pp. 4459-4462, 2005.

[48] D. Stead, P. O'Brien, “Total synthesis of the lupin alkaloid cytisine: comparison of synthetic strategies and routes”, Tetrahedron, vol. 63, 1885-1897, 2007.

[49] F. Bohlmann, N. Ottawa, R. Keller, I. Nebel, J. Politt, Lupinen-Alkaloide, I. Aufbau des “Tetrahydro-chinolizons und des "Bispidins" (Beitr?ge zur Synthese des Cytisins)”, Justus Liebigs Annuals Chemistry, vol. 587, pp. 162-176, 1954.

[50] J.W. Coe, H. Rollema, B.T. O’Neil, Case history: Chantix?Champix? (varenicline Tartrate), a nicotinic acetylcholine receptor partial agonist as a smoking cessation aid, Annual Reports in Medicinal Chemistry, vol. 44, pp. 71, 2009.

[51] C. Hirschh?user, C. A. Haseler, T. Gallagher, “Core Modification of Cytisine: A Modular Synthesis”, Angewandte Chemie International Edition, vol. 50, pp. 5162-5165, 2011.

[52] Y.E. Slater, L.M. Houlihan, P.D. Maskell, R. Exley, I. Bermu?dez, R.J. Lukas, A.C. Valdivia, B.K. Cassels, “Halogenated cytisine derivatives as agonists at human neuronal nicotinic acetylcholine receptor subtypes”, Neuropharmacology vol. 44, pp. 503-513, 2003.

[53] U.S. Makhmudov, K.K. Turgunov, B. Tashkhodzhaev, V.A. Saprykina, K.M. Shakhidoyatov, “Crystalsolvates of N-(3-ethylthio-1,2,4-thiadiazol-5-yl-aminocarbonylmethyl)cytisine, Chemistry of Natural Compounds, vol. 44, pp. 466-471, 2008.

[54] T.S. Rao, L.D. Correa, R.T. Reid, G.K. Lloyd, “Evaluation of anti-nociceptive effects of neuronal nicotinic acetylcholine receptor (NAChRs) ligands in the rat tail-flick assay”, Neuropharmacology, vol. 35, pp. 393-405, 1996.

[55] Y.E. Later, L.M. Houlihan, P.D. Maskell, R. Exley, I. Bermúdez, R.J. Lukas, A.C. Valdivia, B.K. Cassels, “Halogenated cytisine derivatives as agonists at human neuronal nicotinic acetylcholine receptor subtypes”, Neuropharmacology vol. 44, pp. 503-515, 2003.

[56] J.W. Coe, H. Rollema, B.T. O’Neill, “Progress in Heterocyclic chemistry”, Annual Reports Meicinal Chemistry, vol. 44, pp. 71, 2009.

[57] J.W. Sloan, W.R. Martin, M. Bostwick, R. Hook, E. Wala, “The comparative binding characteristics of nicotinic ligands and their pharmacology”, Pharmacology Biochemistry & Behavior, vol. 30, pp. 255-267, 1988.

[58] L.A. Pabreza, S. Dhawan, K.J. Kellar, “[3H] cytisine binding to nicotinic cholinergic receptors in brain”, Molecular Pharmacology, vol. 39, pp. 9-12, 1991.

[59] O. Nicolotti, C. Canu Boido, F. Sparatore, A. Carotti, “Cytisine derivatives as high affinity nAChR ligands: synthesis and comparative molecular field analysis”, Farmaco vol. 57, pp. 469-478, 2002.

[60] E. Carbonnelle, F. Sparatore, C. Canu Boido, C., Salvagno, B. Baldani-Guerra, G. Terstappen, R. Zwart, H. Vijverberg, F. Clementi, C. Gotti, “Nitrogen substitution modifies the activity of cytisine on neuronal nicotinic receptor subtypes”, European Journal of Pharmacology, vol. 471, pp. 85-96, 2003.

[61] B. Tasso, C. Canu Boido, E. Terranova, C. Gotti, L. Riganti, F. Clementi, R. Artali, G. Bombieri, F. Meneghetti, F. Sparatore, “Synthesis, binding, and modeling studies of new cytisine derivatives, as ligands for neuronal nicotinic acetylcholine receptor subtypes”, Journal of Medicinal Chemistry. vol. 52, pp. 4345-4357, 2009.

[62] I. Murakoshi, K. Fukuchi, J. Haginiwa, S. Ohmiya, H. Otomasu, “N-(3oxobutyl)cytisine: a new lupin alkaloid from Echinosophora koreensis”, Phytochemistry, vol. 16, pp. 1460, 1977.

[63] S.K. Chellappan, Y. Xiao, W. Tueckmantel, K.J. Kellar, A.P. Kozikowski, “Synthesis and pharmacological evaluation of novel 9- and 10-substituted cytisine derivatives. Nicotinic ligands of enhanced subtype selectivity”, Journal of Medicinal Chemistry, vol. 49, pp. 2673-2676, 2006.

[64] E. Schmidt, J. Lammers, “Beitr?ge zur Kenntnis des Cytisins”, Archives of Pharmacy, vol. 235, pp. 374-394, 1897.

[65] A. Orjales, I. Ribas, A. Varela, Annuals of Quimistry, vol. 68, pp. 1419-1422, 1972.

[66] N. Houllier, J. Gopisetti, P. Lestage, M.-C. Lasne, J. Rouden, “Identification of 9-fluoro substituted (-)-cytisine derivatives as ligands with high affinity for nicotinic receptors”, Bioorganic and Medicinal Chemistry Letters, vol. 20, pp. 6667-6670, 2010.

[67] R.W. Fitch, Y. Kaneko, P. Klaperski, J.W. Daly, G. Seitz, D. Gündisch, “Halogenated and isosteric cytisine derivatives with increased affinity and functional activity at nicotinic acetylcholine receptors”, Bioorganic and Medicinal Chemistry Letters, vol. 15, pp. 1221-1224, 2005.

[68] Y.S. Mineur, C. Eibl, G. Young, C. Kochevar, R.L. Papke, D. Gundisch, M.R. Picciotto, “Cytisine-based nicotinic partial agonists as novel antidepressant compounds”, Journal of Pharmacological and Experimentals Therapies, vol. 329, pp. 377-386, 2009.

[69] Y.S. Mineur, E.B. Einstein, P.A. Seymour, J.W. Coe, B.T. O’Neill, H. Rollema, M.R. Picciotto, “α4β2 nicotinic acetylcholine receptor partial agonists with low intrinsic efficacy have antidepressantlike properties”, Behavioural Pharmacology, vol. 22, pp. 291-299, 2011.

[70] B.K. Cassels, I. Bermudez, F. Dajas, J.A. Abin-Carriquiry, S. Wonnacottd, “From ligand design to therapeutic efficacy: the challenge for nicotinic receptor research”, Drug Discovery Today vol. 10, pp.1657-1665, 2005.

[71] P.A. Crooks, M.T. Bardo, L.P. Dwoskin, Nicotinic receptor antagonists as treatments for nicotine abuse, Advances in Pharmacology vol. 69, pp. 513-551, 2014.

[72] K. Cahill K, N. Lindson-Hawley, K.H. Thomas, T.R. Fanshawe, T. Lancaster, “Nicotine receptor partial agonists for smoking cessation“, Database Systematic Review, DOI: 10.1002/14651858.CD006103.pub7, 2016.

[73] F.R. Struth, C. Hirschh?user, “A Modular Approach to the Asymmetric Synthesis of Cytisine”, European Journal of Organic Chemistry, DOI: 10.1002/ejoc.201501435, 2016.

[74] D. Bartusik, D. Aebisher, P. Tutka, “In vivo imaging studies of cytisine”, Biointerface Research in Applied Chemistry, vol. 6, pp. 1288-1290, 2016.